NovaGo Therapeutics AG Secures $30 Million in Series B Funding

NovaGo Therapeutics AG Secures $30 Million in Series B Funding

NovaGo Therapeutics AG, a biotechnology company based in Schlieren, Switzerland, has successfully raised $30 million in a Series B funding round. The company focuses on developing therapies that target Nogo-A, an inhibitor of nerve-fiber growth, with the aim of enhancing functional recovery following spinal cord injuries.

Investors and Funding Details

The Series B round was led by Neurimmune and Pureos, with additional participation from the Swiss Paraplegic Foundation and Wings for Life. This infusion of capital is expected to propel NovaGo Therapeutics AG forward in its mission to improve outcomes for individuals suffering from spinal cord injuries.

Planned Use of Funds

While specific plans for the newly raised funds were not disclosed, it is anticipated that the capital will be utilized to further the development of the company’s lead program targeting Nogo-A, potentially bringing new therapies closer to market.

About NovaGo Therapeutics AG

NovaGo Therapeutics AG is at the forefront of developing innovative treatments aimed at restoring sensation and enhancing recovery following spinal cord injuries. By targeting Nogo-A, the company seeks to promote nerve-fiber growth and improve functional outcomes for patients.

For more information about NovaGo Therapeutics AG and their work, visit their website.